NewLink Genetics Corporation (NASDAQ:NLNK) Files An 8-K Other Events

ME Staff 8-k
-
0

NewLink Genetics Corporation (NASDAQ:NLNK) Files An 8-K Other Events

Item 8.01. Other Events.

On June 23, 2017, NewLink Genetics Corporation, a Delaware
corporation, or the Company, issued a press release titled
“Positive Phase 1b Data for NewLink Genetics IDO Pathway
Inhibitor, Indoximod, in Combination with Chemotherapy for
Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
Presented at the European Hematologic Association (EHA) Congress
in Madrid, Spain.”
A copy of the press release is attached hereto as Exhibit 99.1
and is incorporated herein by reference.
Section 9 – Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number
Description
99.1
Press Release, dated June 23, 2017, entitled Positive
Phase 1b Data for NewLink Genetics IDO Pathway
Inhibitor, Indoximod, in Combination with Chemotherapy
for Patients with Newly Diagnosed Acute Myeloid
Leukemia (AML) Presented at the European Hematologic
Association (EHA) Congress in Madrid, Spain



NEWLINK GENETICS CORP Exhibit
EX-99.1 2 nlnk-20170623x8kxex991.htm PRESS RELEASE Exhibit Exhibit 99.1FOR IMMEDIATE RELEASEPositive Phase 1b Data for NewLink Genetics’ IDO Pathway Inhibitor,…
To view the full exhibit click here
About NewLink Genetics Corporation (NASDAQ:NLNK)

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system. Algenpantucel-L is its clinically advanced product candidate for patients with pancreatic cancer. Its additional HyperAcute cellular HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma. It has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system’s tolerance to cancer.